10.1038/nature12328 Nature 66 LundA.BaggerJ
These findings are further supported by another sub-analysis of SURMOUNT1, which reported a 33.9% (8.2% for placebo) reduction in fat mass and a 10.9% (2.6% for placebo) reduction in lean mass by week 72, with approximately 75% of weight loss attributable to fat mass, consistent across clinically relevant subgroups [68]
Orders can only be canceled before they ship
The FDA-approved dose escalation schedules for these medications are specifically designed to minimize side effects by allowing gradual physiological adaptation
But here is the catch
Retatrutide, Amycretin, Survodutide, VK2735, and MariTide are among the most watched pipeline assets heading into 2026 because each represents a different answer to the same commercial question: what comes after Ozempic, Wegovy, Mounjaro, and Zepbound